Phaseline

Targets › ZAP70

ZAP70 (Tyrosine-protein kinase ZAP-70): drug programs, companies and trials

1 program from 1 company in 8 trials: 4 Phase 3, 4 Phase 2; Immunology; next expected readout Feb 2027.

Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates motility, adhesion and cytokine expression of mature T-cells, as well as thymocyte development. (UniProt, P43403)

Open in Phaseline: the race on ZAP70, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaZasocitinib
TEC kinase inhibitor
TEC, ZAP70Phase 3Psoriatic Arthritis; Plaque Psoriasis; Hidradenitis Suppurativa; Nonsegmental Vitiligo …Feb 2027

Conditions

Psoriatic Arthritis (3) Crohn's Disease (2) Plaque Psoriasis (1) Hidradenitis Suppurativa (1) Nonsegmental Vitiligo (1)

Modalities

small molecule (1)

Companies

Takeda (1)

Related targets

TEC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.